On August 28, MEDBOT-B fell 5.5% in regular trading, trading at HKD 21.62/share, with turnover of HKD 75.84 million.

The decline was triggered by a cluster of announcements released on the evening of August 27. The company disclosed that its board meeting originally scheduled for August 27 to review interim results has been postponed to August 31, as management requires additional time to finalize financial data for the six months ended June 30. Simultaneously, executive director Liu Yu resigned from his position and the commercialization committee, while non-executive director Liang Min tendered her resignation from the board, nomination committee, and commercialization committee.

The board nominated Jonathan W Chen and Hui Qing as non-executive director candidates, subject to approval at an extraordinary general meeting. The interim results delay raised market concerns regarding the progress of financial data confirmation, despite the company having previously guided for its first-ever half-year profit of RMB 28-40 million on revenue growth of 200%-230% year-over-year. The management reshuffle compounded short-term uncertainty.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)